Novo Nordisk Invests $1.2 Billion in Rare Disease Production Facility in Denmark, Creating 400 New Jobs

Investment:
Novo Nordisk is investing $1.2 billion (8.5 billion Danish kroner) in a new production facility and warehouse in Odense, Denmark, to produce drugs for rare diseases such as hemophilia24.

Job Creation:
The new facility is expected to create 400 permanent jobs once completed in 202724.

Facility Details:
The production facility and warehouse will span over 40,000 square meters (about 430,556 square feet) and will utilize advanced technology and innovative equipment to ensure high-quality production24.

Purpose:
The facility aims to meet the growing global demand for Novo Nordisk's life-changing medicines, particularly for rare diseases24.

Background:
This investment is part of Novo Nordisk's broader efforts to expand its manufacturing capacity, following recent investments in metabolic medicines production in Denmark and France4.

Sources:

2. https://www.dailysabah.com/business/economy/novo-nordisk-invests-12b-to-build-new-factory-in-denmark

4. https://medcitynews.com/2024/12/novo-nordisk-rare-disease-drug-manufacturing-hemophilia-odense-denmark/